# AstraZeneca

Clinical pipelines — Accelerated trials.

Source: https://en.bioecon.ru/companies/astrazeneca/
Updated: 2026-07-02

- Country: United Kingdom

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | CSPC Pharmaceuticals collaboration $4.7bn upfront and milestone payments | https://www.proactiveinvestors.co.uk/companies/news/1087094/astrazeneca-lifts-earnings-as-pipeline-delivery-and-global-expansion-underpin-growth-1087094.html |
| Capacity | Macclesfield site: 72 million packs of medicine; Liverpool site: 20 million vaccine doses annually | https://careers.astrazeneca.com/united-kingdom |
| Regulatory approval | 43 regulatory approvals in major markets in FY 2025; 8 first approvals in H1 2026; 30 approvals in major regions since Q4 2025 results | https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2025/pdf/AstraZeneca_AR_2025_CEO_Review.pdf, https://www.proactiveinvestors.co.uk/companies/news/1087094/astrazeneca-lifts-earnings-as-pipeline-delivery-and-global-expansion-underpin-growth-1087094.html |
| Production site | Macclesfield (pharmaceutical manufacturing), Speke (biologics), and Liverpool (vaccines) | https://careers.astrazeneca.com/united-kingdom |
| Headcount | Approximately 10,000 employees in the UK | https://careers.astrazeneca.com/united-kingdom, https://www.astrazeneca.co.uk/content/dam/intelligentcontent/unbranded/astrazeneca/uk/en/pdf/AstraZeneca-UK-Purpose-Led-Partnerships-Prospectus-2025.pdf |
| Revenue | Total Revenue $58.7 billion for FY 2025; $30.672 billion for H1 2026 | https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2025/pdf/AstraZeneca_AR_2025_CEO_Review.pdf, https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html, https://www.proactiveinvestors.co.uk/companies/news/1087094/astrazeneca-lifts-earnings-as-pipeline-delivery-and-global-expansion-underpin-growth-1087094.html |

Independent sources: proactiveinvestors.co.uk

## Technologies

- [Antibody-drug conjugates (ADCs)](https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/)
- [Corporate biotech accelerators (JLABS, Bayer CoLaborator)](https://en.bioecon.ru/technology/corporate-biotech-accelerators/)